Acadia ( ACAD ) is successfully navigating the dangerous trek from FDA approval to commercial success. It still has a way to go. At this stage it has established a track record of success in marketing its Nuplazid (pimavanserin) therapy for its approved indication. Acadia's existing FDA appr...

ACADIA Pharmaceuticals ( ACAD +17.3% ) is up on double normal volume after posting better-than-expected Q2 results after the close yesterday. Highlights: More news on: ACADIA Pharmaceuticals Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more...

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2019 Earnings Conference Call July 31, 2019 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Steve Davis - Chief Executive Officer Michael Yang - Chief Commercial Officer Serge Stankovic - President Elen...